# Efficacy and Safety of Liraglutide Versus Placebo as add-on to Existing Diabetes Medication in Subjects With Type 2 Diabetes and Moderate Renal Impairment

> **NCT01620489** · PHASE3 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 279 (actual)

## Conditions studied

- Diabetes
- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** liraglutide
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT01620489
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-06-14
- **Primary completion:** 2013-08-20
- **Final completion:** 2013-08-20
- **Target enrollment:** 279 (ACTUAL)
- **Last updated:** 2019-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01620489

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01620489, "Efficacy and Safety of Liraglutide Versus Placebo as add-on to Existing Diabetes Medication in Subjects With Type 2 Diabetes and Moderate Renal Impairment". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT01620489. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*